Lantz Financial LLC Buys 220 Shares of Amgen Inc. (NASDAQ:AMGN)

Lantz Financial LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 14.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,794 shares of the medical research company’s stock after buying an additional 220 shares during the quarter. Lantz Financial LLC’s holdings in Amgen were worth $467,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. MBB Public Markets I LLC increased its stake in Amgen by 54.0% in the second quarter. MBB Public Markets I LLC now owns 75,712 shares of the medical research company’s stock worth $23,656,000 after purchasing an additional 26,553 shares during the period. Marathon Capital Management increased its stake in Amgen by 30.1% in the 2nd quarter. Marathon Capital Management now owns 1,188 shares of the medical research company’s stock worth $371,000 after buying an additional 275 shares during the period. Lighthouse Investment Partners LLC bought a new stake in Amgen during the 2nd quarter valued at about $15,155,000. Scientech Research LLC boosted its position in Amgen by 442.1% in the 2nd quarter. Scientech Research LLC now owns 4,955 shares of the medical research company’s stock valued at $1,548,000 after buying an additional 4,041 shares during the period. Finally, Savvy Advisors Inc. grew its stake in Amgen by 4.8% in the 2nd quarter. Savvy Advisors Inc. now owns 41,302 shares of the medical research company’s stock worth $12,905,000 after acquiring an additional 1,902 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.9 %

Shares of Amgen stock opened at $275.42 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm’s 50 day simple moving average is $271.39 and its two-hundred day simple moving average is $305.99. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a market capitalization of $148.05 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the business posted $4.96 EPS. Analysts predict that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.46%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 115.24%.

Analysts Set New Price Targets

Several analysts have recently weighed in on AMGN shares. Wells Fargo & Company decreased their price target on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Barclays lifted their price objective on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 target price on shares of Amgen in a report on Friday. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $314.65.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.